Author

M. Andreoni

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Di Lorenzo· 1 shared A. Lodi· 1 shared A. Magrini· 1 shared A. Miani· 1 shared A. Romeo· 1 shared A. Sinigaglia· 1 shared A. Terrinoni· 1 shared C. Chiaramonte· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

A. Di Lorenzo

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection

M. Severa, R. A. Diotti, M. P. Etna, F. Rizzo, S. Fiore, D. Ricci, M. Iannetta, A. Sinigaglia, A. Lodi, N. Mancini, E. Criscuolo, M. Clementi, M. Andreoni, S. Balducci, L. Barzon, , E. Coccia

This study compares plasmacytoid dendritic cell (pDC) phenotype and type I IFN response in asymptomatic and severe COVID-19 patients, finding differences in pDC frequency, phenotype, and cytokine levels.

bioRxiv · Apr 17, 2021Immunology

Lactoferrin as potential supplementary nutraceutical agent in COVID-19 patients: in vitro and in vivo preliminary evidences

E. Campione, C. Lanna, T. Cosio, L. Rosa, M. P. Conte, F. Iacovelli, A. Romeo, M. Falconi, C. Del Vecchio, E. Franchin, M. S. Lia, M. Minieri, C. Chiaramonte, M. Ciotti, M. Nuccetelli, , L. Bianchi

This paper investigates lactoferrin's antiviral activity against SARS-CoV-2 through in vitro and in vivo studies, showing it reduces viral RNA conversion time and inflammation markers in COVID-19 patients.

bioRxiv · Aug 11, 2020 · PreprintMicrobiology